Extended-Release Naltrexone vs. Buprenorphine-Naloxone for Preventing Opioid Relapse

被引：0
|
作者：
不详
机构：
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 02期
关键词：
D O I：
10.1016/S01406736(17)32812-X
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [31] Safety of combination buprenorphine/naloxone and extended release naltrexone
    Lindblad, R.
    Saxon, A.
    VanVeldhuisen, Paul
    Lu, L.
    Hu, L.
    Hasson, A.
    Thomas, C.
    Sparenborg, Steven
    Mooney, Larissa
    Ling, W.
    DRUG AND ALCOHOL DEPENDENCE, 2017, 171 : E121 - E121
  • [32] Extended-Release Naltrexone for Opioid Relapse Prevention at Jail Re-Entry
    Lee, Joshua D.
    McDonald, Ryan
    Santana-Correa, Nadina
    Rotrosen, John
    Gourevitch, Marc N.
    SUBSTANCE ABUSE, 2014, 35 (02) : 195 - 195
  • [33] Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD
    Wang, An-Li
    Shulman, Matisyahu
    Choo, Tse-Hwei
    Pavlicova, Martina
    Langleben, Daniel D.
    Nunes, Edward V.
    Rotrosen, John
    ADDICTION BIOLOGY, 2022, 27 (02)
  • [34] Comparison of the risk of drop-out from opioid maintenance treatment in patients using naltrexone implants vs. oral buprenorphine-naloxone
    Kirli, Umut
    Nart, Omer
    KLINIK PSIKIYATRI DERGISI-TURKISH JOURNAL OF CLINICAL PSYCHIATRY, 2021, 24 (03): : 342 - 349
  • [35] Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study (vol 76, pg 127, 2018)
    Latif, Z. E. H.
    Benth, Saltyte J.
    Solli, K. K.
    JAMA PSYCHIATRY, 2019, 76 (02) : 219 - 219
  • [36] Co-occurring Depression in Patients With Opioid Use Disorder: Prevalence and Response During Treatment With Buprenorphine-Naloxone or Extended- Release Naltrexone
    Na, Peter
    Scodes, Jennifer
    Pavlicova, Martina
    Fishman, Marc
    Rotrosen, John
    Nunes, Edward
    AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (03): : 253 - 253
  • [37] Injectable extended-release naltrexone for opioid dependence
    Throckmorton, Douglas C.
    Temple, Robert
    Rappaport, Bob A.
    Roca, Rigoberto
    Winchell, Celia J.
    LANCET, 2011, 378 (9792): : 665 - 666
  • [38] Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone
    Tsui, Judith I.
    Campbell, Aimee N. C.
    Pavlicova, Martina
    Choo, Tse-Hwei
    Lee, Joshua D.
    Cook, Ryan R.
    Shulman, Matisyahu
    Nunes, Edward, V
    Rotrosen, John
    DRUG AND ALCOHOL DEPENDENCE, 2022, 236
  • [39] A Comparison of Neuropsychological Functioning between Patients With Opioid Use Disorders on Extended-Release Naltrexone and Buprenorphine
    Castillo, Felipe
    Campbell, Aimee
    Choo, Tse-Hwei
    Pavlicova, Martina
    Rotrosen, John
    Selzer, Jeffrey A.
    Nunes, Edward, V
    DRUG AND ALCOHOL DEPENDENCE, 2025, 267
  • [40] NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale
    Lee, Joshua D.
    Nunes, Edward V.
    Novo, Patricia
    Bailey, Genie L.
    Brigham, Gregory S.
    Cohen, Allan J.
    Fishman, Marc
    Ling, Walter
    Lindblad, Robert
    Shmueli-Blumberg, Dikla
    Stablein, Don
    May, Jeanine
    Salazar, Dagmar
    Liu, David
    Rotrosen, John
    CONTEMPORARY CLINICAL TRIALS, 2016, 50 : 253 - 264
12345